Hartung HP - Search Results

1

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD; SPI2 investigative teams. Cree BAC, et al. Among authors: hartung hp. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23. Lancet Neurol. 2020. PMID: 33222767 Clinical Trial.

2

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung H, Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR; Early Treatment of Multiple Sclerosis Study Group. Comi G, et al. Lancet. 2001 May 19;357(9268):1576-82. doi: 10.1016/s0140-6736(00)04725-5. Lancet. 2001. PMID: 11377645 Clinical Trial.

3

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Hartung HP, et al. Lancet. 2002 Dec 21-28;360(9350):2018-25. doi: 10.1016/S0140-6736(02)12023-X. Lancet. 2002. PMID: 12504397 Clinical Trial.

4

Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele.

Enzinger C, Ropele S, Strasser-Fuchs S, Kapeller P, Schmidt H, Poltrum B, Schmidt R, Hartung HP, Fazekas F. Enzinger C, et al. Among authors: hartung hp. Arch Neurol. 2003 Jan;60(1):65-70. doi: 10.1001/archneur.60.1.65. Arch Neurol. 2003. PMID: 12533090

5

Interferons in relapsing remitting multiple sclerosis.

Freedman M, King J, Oger J, Sharief M, Hartung HP; PRISMS study investigators. Freedman M, et al. Among authors: hartung hp. Lancet. 2003 May 24;361(9371):1822-3; author reply 1823-4. doi: 10.1016/S0140-6736(03)13419-8. Lancet. 2003. PMID: 12781558 No abstract available.

6

Current disease-modifying therapies in multiple sclerosis.

Kieseier BC, Hartung HP. Kieseier BC, et al. Among authors: hartung hp. Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138. Semin Neurol. 2003. PMID: 12894379 Review.

7

Statins as potential therapeutic agents in multiple sclerosis.

Stüve O, Prod'homme T, Youssef S, Dunn S, Neuhaus O, Weber M, Hartung HP, Steinman L, Zamvil SS. Stüve O, et al. Among authors: hartung hp. Curr Neurol Neurosci Rep. 2004 May;4(3):237-44. doi: 10.1007/s11910-004-0044-2. Curr Neurol Neurosci Rep. 2004. PMID: 15102350 Review.

8

Are statins a treatment option for multiple sclerosis?

Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Neuhaus O, et al. Among authors: hartung hp. Lancet Neurol. 2004 Jun;3(6):369-71. doi: 10.1016/S1474-4422(04)00770-7. Lancet Neurol. 2004. PMID: 15157852 Review.

9

Assessment and management of neutralizing antibodies in patients with multiple sclerosis.

Hartung HP, Munschauer FE 3rd. Hartung HP, et al. J Neurol. 2004 Jun;251 Suppl 2:II40-2. doi: 10.1007/s00415-004-1207-4. J Neurol. 2004. PMID: 15264111

10

European validation of a standardized clinical description of multiple sclerosis.

Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP, Kappos L, Thompson A, Trojano M, Vukusic S, Confavreux C; Evaluation of the EDMUS system (EVALUED) Study Group. Amato MP, et al. Among authors: hartung hp. J Neurol. 2004 Dec;251(12):1472-80. doi: 10.1007/s00415-004-0567-0. J Neurol. 2004. PMID: 15645346

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,122 results

Search Page